SCRT
Drug4 capsules,three times daily, for 7days or within symptom disappearance
Other names: Xiao-qing-long-tang
NCT Number: NCT01019889
The purpose of this study is to determine whether Socheongryong-tang (SCRT) and Yeongyopaedok-san (YPS) are effective in the treatment of upper respiratory tract infection.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 3
Upper respiratory tract infections (URTIs) are the most prevalent disease of human beings, it incur a significant health burden on populations in terms of human suffering and economic losses. Usually, antibiotic therapy is not helpful since most infections are virally induced. Over 200 serologically different viral types are responsible for human URTIs, so that preventions of URTIs including vaccination are impassable. SCRT and YPS are widely used to treat the respiratory disease. The objective of this study is to determine the efficacy of SCRT and YPS in symptomatic relief of patients with URTIs.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
4 capsules,three times daily, for 7days or within symptom disappearance
Other names: Xiao-qing-long-tang
4 capsules, three times daily, for 7days or within symptom disappearance
Other names: Lian-qiao-bai-du-san
4 capsules, three times daily, for 7days or within symptom disappearance
Time frame: daily (7 days)
Time frame: daily
Time frame: daily (7days)
Korea Health Industry Development Institute
Other Gov
Acronym: ESYUI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07552779
COVID-19, COVID-19 (Coronavirus Disease 2019)
Brussels, Bruxelles-capitale, Région de, Belgium
View Trial DetailsNCT04155892
Infections, Respiratory Tract Diseases
Winston-Salem, North Carolina, United States
View Trial DetailsNCT06149494
COPD, COPD Exacerbation Acute
London, United Kingdom
View Trial DetailsNCT05577065
Infections, Respiratory Tract Diseases
Cork, Ireland
View Trial Details